- Home
- POLA vs LGVN Comparison
POLA vs LGVN Comparison
Compare POLA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- LGVN
- Stock Information
- Founded
- POLA 1979
- LGVN 2014
- Country
- POLA United States
- LGVN United States
- Employees
- POLA N/A
- LGVN N/A
- Industry
- POLA Industrial Machinery/Components
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- POLA Miscellaneous
- LGVN Health Care
- Exchange
- POLA Nasdaq
- LGVN Nasdaq
- Market Cap
- POLA N/A
- LGVN 30.0M
- IPO Year
- POLA 2016
- LGVN 2021
- Fundamental
- Price
- POLA $0.45
- LGVN $2.05
- Analyst Decision
- POLA
- LGVN Strong Buy
- Analyst Count
- POLA 0
- LGVN 2
- Target Price
- POLA N/A
- LGVN $8.00
- AVG Volume (30 Days)
- POLA 454.1K
- LGVN 393.9K
- Earning Date
- POLA 11-12-2024
- LGVN 11-08-2024
- Dividend Yield
- POLA N/A
- LGVN N/A
- EPS Growth
- POLA N/A
- LGVN N/A
- EPS
- POLA N/A
- LGVN N/A
- Revenue
- POLA $11,950,000.00
- LGVN $1,229,000.00
- Revenue This Year
- POLA $6.72
- LGVN $161.78
- Revenue Next Year
- POLA N/A
- LGVN $8.62
- P/E Ratio
- POLA N/A
- LGVN N/A
- Revenue Growth
- POLA N/A
- LGVN 39.34
- 52 Week Low
- POLA $0.32
- LGVN $0.77
- 52 Week High
- POLA $0.98
- LGVN $23.90
- Technical
- Relative Strength Index (RSI)
- POLA 49.24
- LGVN 52.20
- Support Level
- POLA $0.44
- LGVN $1.76
- Resistance Level
- POLA $0.54
- LGVN $2.26
- Average True Range (ATR)
- POLA 0.07
- LGVN 0.12
- MACD
- POLA -0.01
- LGVN 0.05
- Stochastic Oscillator
- POLA 20.00
- LGVN 58.00
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.